Non-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts
for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85 …

Cancer is amenable to low-cost treatments, given that it has a significant metabolic
component, which can be affected through diet and lifestyle change at minimal cost. The …

Previously used in anti-fungal therapy, itraconazole has now been shown to be successful in
treating advanced breast cancer (NCT00798135). However, its poor solubility still restricts its …

The antifungal drug itraconazole has been repurposed to anti-angiogenic agent, but the
mechanisms of action have been elusive. Here we report that itraconazole disrupts focal …

Background/Aim: Combination chemotherapy with gemcitabine, nab-paclitaxel, oxaliplatin,
and itraconazole (GnPO-ITC) was administered as first-line chemotherapy in patients with …

Simple Summary We present eight core attributes of cancer growth that we must address for
a more effective treatment than we currently have. To do this we outline why a regimen …

Itraconazole, an FDA-approved antifungal, has antitumor activity against a variety of
cancers. We sought to determine the effects of itraconazole on esophageal cancer and …

Oncology research progresses, yet cancer remains the largest medical need. The use of a
medication with an accessible lead molecule shows great potential for long-term cancer …

Itraconazole is an oral antifungal that has a been reported to have anticancer effect in non-
small cell lung cancer (NSCLC) through inhibition of angiogenesis. The aim is to evaluate …

Triple-negative breast cancer (TNBC) is the aggressive molecular type of breast carcinoma,
with a high metastasis/relapse incidence and cancer-related death rate, due to lack of …